Trends-in-Medicine| Publisher: | Stephen Snyder |
| Writers: | Lynne Peterson |
| Marta Weber | |
| Diana Woods | |
| Editors: | Kathleen Snyder |
| Betty Teel | |
Trends-in-Medicine has no financial connections with any pharmaceutical or medical device company. The information and opinions expressed have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter.
Copyright© 2004
No articles may be reproduced without written permission of the publisher.
Return Home
The Family Medicine Perspective - Quick Pulse
Summary: Family medicine doctors often write more prescriptions for particular medicines than their specialist counterparts, so understanding their attitudes toward a variety of topics and their clinical practices are very important in determining the outlook for new drugs and devices as well as expanded labels for existing products. At the American Academy of Family Practice (AAFP) annual meeting in Orlando, FL from October 13-17, 2004, 21 primary care doctors were questioned on a variety of topics, from antidepressants and diet drugs to medications to treat hyperlipidemia, diabetes, and excessive daytime sleepiness.
The Future of AstraZeneca’s Crestor - Quick Pulse
Summary: As of the end of November 2004, the FDA still had not responded to a consumer watchdog organization’s petition in March 2004, asking the FDA to remove AstraZeneca’s Crestor (rosuvastatin) from the market. The FDA is supposed to respond to petition like this within six months, in this case by September 3, 2004, but there is no penalty for taking longer. Predicting what the FDA will do in this case is difficult, but the issue gained new visibility recently when an FDA official told a congressional committee that he had safety concerns about Crestor.
The Cardiovascular Safety of Cox-2 Inhibitors - Quick Pulse
Summary: With Merck’s Vioxx (rofecoxib) now off the market, how safe are the other Cox-2 inhibitors on the market – Pfizer’s Celebrex (celecoxib) and Bextra (valdecoxib)? What do the cardiovascular problems with Vioxx mean for other Cox-2 inhibitors in development, including Merck's Arcoxia (etoricoxib) and Novartis’s Prexige (lumiracoxib)? There is no easy or quick answer, and this issue may haunt these products for some time.
1879 Avenida Dracaena, Jensen Beach, FL, 34957, 772-334-7409, Fax 772-334-0856
Email webmaster about site: snyderk577@aol.com
